San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...

Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...

KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter device occlusion of a ...

In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...

A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...

Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, according to research ...

Kolkata: A premature newborn girl, weighing only 720 g, underwent a cardiac procedure—that is usually considered for babies only after they have attained at least 5 kg weight—on the eighth day after ...